Tango Therapeutics (TNGX) Change in Receivables (2023)
Tango Therapeutics' (TNGX) quarterly Change in Receivables came in at -$2.0 million in Q1 2023.
Tango Therapeutics (TNGX) Change in Receivables (2023) Analysis & Trends
Tango Therapeutics' Change in Receivables history runs 1 years deep, the most recent figure standing at -$2.0 million for Q1 2023.
- On a quarterly basis, Change in Receivables changed N/A year-over-year to -$2.0 million in Q1 2023; TTM through Dec 2023 was -$2.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at -$2.0 million, changed N/A from the prior year.
- Change in Receivables was little changed at -$2.0 million in Q1 2023 per TNGX's latest filing.
- Across five years, Change in Receivables topped out at -$2.0 million in Q1 2023 and bottomed at -$2.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tango Therapeutics | 3.94 Bn | 3.78 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -2.00 Mn |
| Mar 31, 2023 | -2.00 Mn |